Evidence receipt
SURPASS-CVOT: what the trial found
A plain-language summary of one study: who took part, what they got, what it was compared with, what happened in each group, its limits and who paid for it. One trial. Results are group averages, not a prediction for any one person.
Study: SURPASS-CVOT[1]
Is tirzepatide at least as good as dulaglutide at preventing heart attacks, strokes and cardiovascular deaths in type 2 diabetes with heart disease?
- Who was in it
- 13,299 adults with type 2 diabetes and atherosclerotic cardiovascular disease
- What they got
- Tirzepatide up to 15 mg once a week
- Compared with
- Dulaglutide 1.5 mg once a week (another GLP-1 medicine)
- How long
- Event-driven, multi-year
- What happened
- Heart attack, stroke or cardiovascular death: 12.2% on tirzepatide vs 13.1% on dulaglutide.
- Relative effect
- Hazard ratio 0.92 (95.3% CI 0.83–1.01): non-inferior; superiority not shown
- Limits
- No placebo group — compared with another GLP-1 medicine
- Superiority was not shown
- Funded by
- Eli Lilly
Summary by Joshua Nichvolodoff, from the published paper — not written by the study's authors. Clinical review: not yet reviewed by a clinician.
Sources
- Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). New England Journal of Medicine, December 18, 2025. https://pubmed.ncbi.nlm.nih.gov/41406444/ · DOI 10.1056/NEJMoa2505928 · PMID 41406444. Accessed November 2, 2026. Back to the text
Discussed in: Tirzepatide, explained · Mounjaro, explained
General information, not medical advice.